Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Treatments

Topic: Brain proteins, microglia and lab models

Plain-language summary

La aprobación de lecanemab y donanemab para el tratamiento de la enfermedad de Alzheimer temprana plantea nuevos desafíos para la neurología vascular, principalmente por la aparición de anomalías en las imágenes relacionadas con el amiloide (ARIA). Estas pueden manifestarse como edema vasogénico o derrames sulcales (ARIA-E) y como microhemorragias, siderosis superficial o macrohemorragias (ARIA-H). Entre sus principales factores de riesgo se encuentran el genotipo APOE ε4 y la dosis del fármaco. Aunque suelen ser hallazgos radiológicos, pueden ocasionar déficits neurológicos focales, crisis epilépticas, cefalea o encefalopatía, síntomas que pueden confundirse con eventos cerebrovasculares agudos. La coexistencia de enfermedad de Alzheimer, angiopatía amiloide cerebral, ARIA y enfermedad cerebrovascular exige reconsiderar el uso de anticoagulantes y trombolíticos debido al riesgo de hemorragia intracerebral. Ante la sospecha de ictus en pacientes tratados con terapias anti-β-amiloide, se recomienda realizar una resonancia magnética urgente para descartar ARIA. En casos de oclusión de grandes vasos, la trombectomía mecánica podría ser una alternativa de reperfusión. Se requieren protocolos específicos y una mayor integración entre la neurología cognitiva y vascular para garantizar decisiones terapéuticas seguras.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bombón-Albán, P. E. (2026). Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular. Acta neurológica colombiana. https://doi.org/10.22379/anc.2188

Vancouver

Bombón-Albán PE. Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular. Acta neurológica colombiana. 2026. doi:10.22379/anc.2188.

BibTeX

@article{bombonalban2026-7db0e4e9,
  author  = {Bombón-Albán, Paulina Elizabeth},
  title   = {{Terapia anti β-amiloide y enfermedad cerebrovascular: nuevos retos para la neurología vascular}},
  journal = {Acta neurológica colombiana},
  year    = {2026},
  doi     = {10.22379/anc.2188},
  url     = {https://doi.org/10.22379/anc.2188}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

The approval of lecanemab and donanemab for early Alzheimer's disease raises new challenges for vascular neurology, mainly because of ARIA, which can appear as brain edema or sulcal effusions (ARIA-E) and as microhemorrhages, superficial siderosis, or macrohemorrhages (ARIA-H). The authors note that APOE ε4 genotype and drug dose are main risk factors, that ARIA symptoms can be mistaken for acute cerebrovascular events, and that the coexistence of Alzheimer's disease, cerebral amyloid angiopathy, ARIA, and cerebrovascular disease requires reconsidering the use of anticoagulants and thrombolytics.

Study details

How this study scored 27/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 0 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 27 of 100.27 of 100 points earned73 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Acta neurológica colombiana)
Journal's citation record 0 / 4 Acta neurológica colombiana: journal h-index 11 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 0 / 4 Last-listed author Paulina Elizabeth Bombón-Albán: h-index 3 (OpenAlex, whole career)
Institution's track record 0 / 3 Pontificia Universidad Católica del Ecuador: institution h-index 151 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 27 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →